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ABSTRACT: Oleﬁn metathesis has emerged as a promising
strategy for modulating the stability and activity of biologically
relevant compounds; however, the ability to control oleﬁn
geometry in the product remains a challenge. Recent advances
in the design of cyclometalated ruthenium catalysts has led to
new strategies for achieving such control with high ﬁdelity and
Z selectivity, but the scope and limitations of these catalysts on
substrates bearing multiple functionalities, including peptides,
remained unexplored. Herein, we report an assessment of
various factors that contribute to both productive and
nonproductive Z-selective metathesis on peptides. The inﬂuence of sterics, side-chain identity, and preorganization through
peptide secondary structure are explored by homodimerization, cross metathesis, and ring-closing metathesis. Our results indicate
that the amino acid side chain and identity of the oleﬁn profoundly inﬂuence the activity of cyclometalated ruthenium catalysts in
Z-selective metathesis. The criteria set forth for achieving high conversion and Z selectivity are highlighted by cross metathesis
and ring-closing metathesis on diverse peptide substrates. The principles outlined in this report are important not only for
expanding the scope of Z-selective oleﬁn metathesis to peptides but also for applying stereoselective oleﬁn metathesis in general
synthetic endeavors.
■ INTRODUCTION
Oleﬁn metathesis is a highly versatile tool for the generation of
carbon−carbon bonds, and a variety of applications have
evolved around its implementation.1−5 The broad utility of
oleﬁn metathesis is a consequence of the exceptional selectivity,
activity, and functional-group compatibility of select metathesis
catalysts, highlighted by carbon−carbon bond formation on a
variety of complex substrates including small molecules,6−11
natural products,12,13 organic and inorganic materials,14−18 and
even proteins.19,20 The use of metathesis in biological
applications is an emerging ﬁeld of research, in part, because
of advances in the genetic21−23 and chemical24−26 incorpo-
ration of alkene-containing amino acids into peptides and
proteins. This has enabled the installation of a variety of
carbon−carbon bonds with high ﬁdelity for applications in
peptide stapling,27−34 as surrogates of hydrogen bonding,35−37
and as methods for modifying peptides and proteins used to
mimic physiologically relevant post-translational modiﬁca-
tions.20,38 The application of metathesis for stabilizing peptide
secondary structure and for performing selective protein
modiﬁcations has implications for imparting greater metabolic
stability, cellular permeability, and higher binding aﬃnity
toward biological targets.30,39−41 Indeed, this strategy has led
to the development of “stapled” peptides used as inhibitors of
HIV fusion42 and assembly,43−46 as modulators of signaling
pathways involved in cancer,47−50 and as selective activators of
enzymes involved in diabetes.51,52
Despite the tremendous success of metathesis in peptide and
peptidomimetic research, the ability to control oleﬁn geometry
in the product has been met with limited success.53−55 Most
metathesis catalysts exhibit minimal kinetic selectivity, and thus,
the product distribution reﬂects the thermodynamic stability of
each oleﬁn isomer.56 In many cases, a mixture of E and Z
isomers is formed that is often inseparable. This imposes
challenges for examining the inﬂuence of alkene geometry on
the stability and activity of diverse compounds. In pursuit of
catalysts with greater control over oleﬁn products, we
uncovered a series of cyclometalated ruthenium catalysts that
could achieve high conversions with exquisite Z selectivity
(Figure 1).57−62 The origin of Z selectivity for cyclometalated
ruthenium catalysts involves approach of the oleﬁn from a side-
bound position (i.e., cis to the NHC ligand and trans to the
chelating adamantyl) and is favored through a combination of
steric and electronic eﬀects imposed by the NHC ligand.63
Although catalysts 1 and 2 demonstrate excellent selectivity in
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oleﬁn metathesis, their activity on complex substrates, including
peptides, remained unexplored. To this end, we sought to
initiate a comprehensive evaluation of Z-selective metathesis on
peptides using newly developed cyclometalated ruthenium
catalysts. Through the combined eﬀorts of homodimerization,
cross metathesis and ring-closing metathesis, we have
developed guidelines for assessing the inﬂuence of amino
acids and peptides on catalyst activity and selectivity. These
principles were applied for carrying out Z-selective metathesis
on challenging substrates including peptides that comprise
parallel β-sheets and on stapling of α-helical peptides.
■ RESULTS AND DISCUSSION
Assessing the Amino Acid Substrate Scope by Z-
Selective Homodimerization. Our goal for expanding the
utility of Z-selective ruthenium catalysts was to examine the
inﬂuence of amino acids on the selectivity and activity of
catalysts 1 and 2. Catalysts bearing N-adamantyl substituents
and bidentate nitrato ligands were found to be critical for
achieving high Z selectivity,59 and we set out to determine
whether such catalysts could be applied to substrates bearing
multiple functionalities and with varying steric proﬁles. To
benchmark the reactivities of catalysts 1 and 2, we chose to
investigate the homodimerization of protected amino acids
modiﬁed with homoallyl functionality (Table 1).64 Our initial
studies focused on the use of alanine 3, as we anticipated that
amino acids bearing unhindered and aliphatic side chains would
provide an ideal platform for comparative studies. We began
with a catalyst loading of 2.5 mol % in tetrahydrofuran (THF)
at 40 °C, and this aﬀorded the homodimerization product 4 in
53% yield after 4 h using catalyst 1 and 58% yield in the
presence of catalyst 2 (entry 1). Gratifyingly, the Z selectivity
remained high (∼90%) throughout the course of the reaction.65
An increase in catalyst loading was then examined at varying
concentrations. Catalyst loadings of 5 mol % aﬀorded product 4
in 65% yield with 92% Z selectivity in the presence of catalyst 2
(entry 2). Increasing the concentration led to modest
improvements in yields while maintaining high Z selectivity
(entries 3 and 4). Ultimately, we found that using a catalyst
loading of 7.5 mol % aﬀorded product 4 in 76% yield with 94%
Z selectivity (entry 6), and these conditions proved to be
optimal among the various reaction conditions explored. We
next examined the solvent dependence of the activities of
catalysts 1 and 2 in homodimerization, as this is an important
consideration in view of the solubility proﬁles of many peptidic
substrates (Table 2). Several polar and nonpolar solvents were
investigated reﬂecting those most often used in peptide
synthesis. Coordinating solvents [e.g., acetonitrile (MeCN)]
were less active in promoting Z-selective metathesis as
compared to noncoordinating solvents [e.g., dicholorethane
(DCE)] (entries 2 and 3). Polar solvents including
dimethylformamide (DMF), dimethyl sulfoxide (DMSO), and
N-methylpyrrolidone (NMP) were tolerated by catalysts 1 and
2, aﬀording product 4 in yields ranging from 55% to 67% and
90% Z selectivity (entries 4−6). Protic solvents including
methanol (MeOH), ethanol (EtOH), and aqueous tert-butanol
(t-BuOH) mixtures yielded highly enriched Z-oleﬁn products
(entries 7−9).66 Other polar solvents including nitromethane
(MeNO2) resulted in low conversions (entry 10), presumably
by activating decomposition pathways of the cyclometalated
ruthenium catalysts.67 It is worth noting that, across the variety
of reaction conditions explored, the Z selectivity remained
consistently high.
To probe the activities of catalysts 1 and 2 further, we
investigated the homodimerization of other canonical amino
acids (Table 3). Boc-protected amino acids bearing aliphatic or
aromatic side chains were active in Z-selective metathesis
(entries 1−4). Branched side chains from amino acids including
valine (5a), isoleucine (5b), and leucine (5c) aﬀorded products
Figure 1. Z-selective cyclometalated ruthenium catalysts.









(M) 1 2 1 2
1 2.5 0.4 53 58 89 93
2 5.0 0.2 61 63 86 92
3 5.0 0.4 62 63 91 90
4 5.0 1.0 60 72 91 91
5 7.5 0.2 68 71 90 94
6 7.5 0.4 74 76 91 94
7 7.5 1.0 72 72 90 91
8 10 0.4 72 70 89 93
9 10 1.0 71 72 90 92
aIsolated yields. bDetermined by 1H or 13C NMR spectroscopy.
Table 2. Solvent Eﬀects on Homodimerization of
Homoallyl-Modiﬁed Alanine 3
yielda (%) Z selectivityb (%)
entry solvent 1 2 1 2
1 THF 74 76 91 94
2 MeCN 51 49 88 91
3 DCE 72 72 88 92
4 DMF 55 59 84 87
5 DMSO 57 55 90 90
6 NMP 67 65 87 87
7 MeOH 65 70 85 88
8 EtOH 68 64 88 90
9 H2O/t-BuOH (1:1) 64 70 90 92
10 MeNO2 <10 <10 n.d. n.d.
aIsolated yields. bDetermined by 1H or 13C NMR spectroscopy.
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6a−c in yields approaching 74% with 94% Z selectivity (entries
1−3). Aromatic side chains from amino acids including
phenylalanine 5d aﬀorded product 6d in 75% yield and 93%
Z selectivity in the presence of catalyst 2 (entry 4). Exceptions
include glycine68 and proline,69 as these are inactive in
homodimerization (entries 5 and 6). Amino acids bearing
heterocycles had variable activity. Homodimerization of
tryptophan aﬀorded product 6g in 64% yield with 90% Z
selectivity (entry 7). In contrast, histidine was deemed
incompatible with catalysts 1 and 2 (entry 8).70 Unprotected
alcohols from the side chains of serine 5i or threonine 5j were
tolerated by catalysts 1 and 2 but required protection to reach
acceptable conversions, providing products 6i and 6j in 72%
and 73% yields, respectively (entries 9 and 10). Homodime-
rization of tyrosine aﬀorded product 6k in 64% yield and 87% Z
selectivity in the presence of catalyst 1 and 68% yield and 90%
Z selectivity using catalyst 2 (entry 11). In contrast to alcohols,
side chains bearing thiols (i.e., cysteine) or thioethers (i.e.,
methionine 5l) generally led to catalyst deactivation (entry
12).71 Protecting the side chain of cysteine could overcome
catalyst inactivity and aﬀord product 6m in 55% yield and 87%
Z selectivity (entry 13). Polar side chains bearing carboxylate
(5n,o), carboxamide (5p,q), or amine (5r) functionality
required protection prior to homodimerization. In these
cases, yields from 70% to 80% could be achieved with high Z
selectivity (entries 14−18). Side chains bearing a protected
guanidinium functionality (i.e., arginine 5s) were less active in
homodimerization, aﬀording product 6s in 34% and 33% yields
using catalysts 1 and 2, respectively. These ﬁndings reveal that
the identity of the amino acid side chain can profoundly
inﬂuence the activity of cyclometalated ruthenium catalysts.
Assessing Side-Chain Inﬂuence and Stoichiometry on
Cross Metathesis of Amino Acids. Emboldened by the
success of Z-selective homodimerization of amino acids, we
next evaluated the eﬀects of varying the metathesis partner to
achieve Z-selective cross metathesis (CM) (Table 4). For our
studies, we chose cross partners that showed variable activity in
homodimerization. In this way, we could begin to classify
substrates on the basis of their propensity for achieving
productive CM.72 We explored CM using homoallyl-modiﬁed
alanine 3 and the similarly reactive substrate valine 5a as the
cross partner. Cross metathesis in the presence of an equimolar
ratio of 3 to 5a aﬀorded the desired heterocross product 7 in
41% yield with 90% Z selectivity (entry 1). Increasing the
stoichiometry of 5a relative to 3 led to a modest increase in
yield, providing product 7 in 48% yield with 91% Z selectivity
(entry 2). Further increases in 5a aﬀorded similar trends, with
yields approaching 60% and 90% Z selectivity (entries 3 and 4).
To demonstrate the versatility of this method, we explored
conditions in which 5a was used as the limiting reagent (entries
5−7). Under these conditions, an incremental increase in the
yield of product 7 was observed upon increasing the ratio of 3
to 5a. As in the case of excess 5a, modest improvements in the
yield of 7 were achieved with increasing equivalents of 3,
demonstrating the statistical nature of CM using similar
reactive substrates.73 Given the modest conversions to product
and high Z selectivities, we can conclude that the products of
CM are sparingly consumable using catalysts 1 and 2, ensuring
that the Z selectivity can remain high throughout the course of
the reaction.
We next evaluated whether amino acids of diﬀering reactivity
proﬁles could be used for selective CM (Table 5). In choosing
the requisite cross partners, we focused on substrate 3 and
homoallyl-modiﬁed arginine 5s, as they both showed relatively
low reactivity in homodimerization. We began our studies using
an equimolar ratio of 3 and 5s, and this aﬀorded 8 in 46% yield
and 93% Z selectivity (entry 1). Increasing the ratio of 5s to 3
led to slightly diminished yields and Z selectivities (entries 2−
4).74 By contrast, reversing the order such that 3 was in excess
of 5s aﬀorded 8 in yields of 47% and 58% using catalysts 1 and
2, respectively (entry 5). Further increasing the ratio of 3 to 5s
Table 3. Homodimerization of Canonical Amino Acids for




entry amino acid product 1 2 1 2
1 valine (5a) 6a 74 71 90 94
2 isoleucine (5b) 6b 68 72 88 92
3 leucine (5c) 6c 70 71 88 91
4 phenylalanine (5d) 6d 73 75 89 93
5 glycine (5e) 6e <10 <10 n.d. n.d.
6 proline (5f) 6f <10 <5 n.d. n.d.
7 tryptophan (5g) 6g 66 64 85 90
8 histidine (5h) 6h <5 <5 n.d. n.d.
9 serine (5i) 6i 72 70 84 90
10 threonine (5j) 6i 73 70 88 92
11 tyrosine (5k) 6k 64 68 87 90
12 methionine (51) 61 <5 <10 n.d. n.d.
13 cysteine (5m)c 6m 55 53 87 92
14 aspartic acid (5n)d 6n 61 60 87 90
15 glutamic acid (5o)d 6o 74 71 88 91
16 asparagine (5p)c 6p 70 71 88 91
17 glutamine (5q)c 6q 74 74 88 91
18 lysine (5r)e 6r 78 81 81 89
19 arginine (5s)e 6s 34 33 81 89
aIsolated yields. bDetermined by 1H or 13C NMR spectroscopy. cSide
chain protected with a trityl group. dSide chain protected as the t-butyl
ester. eSide chain protected as the t-butyl carbamate. eSide chain
protected with 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl
(Pbf).




entry equiv of 3 equiv of 5a 1 2 1 2
1 1 1 41 47 90 93
2 1 2 44 48 86 91
3 1 4 48 41 91 90
4 1 6 58 60 88 90
5 2 1 44 58 90 93
6 4 1 52 57 91 91
7 6 1 51 60 87 90
aIsolated yields. bDetermined by 1H or 13C NMR spectroscopy.
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could achieve the heterocross product 8 in improved yields and
high Z selectivities (entries 6 and 7). Taken together, these
ﬁndings reveal that the intrinsic reactivity diﬀerences between
homoallyl-modiﬁed amino acids can be used for productive Z-
selective cross metathesis.
Inﬂuence of Allylic Heteroatoms on Homodimeriza-
tion and Cross Metathesis of Noncanonical Amino
Acids. The unique reactivity proﬁles of canonical amino
acids in Z-selective homodimerization and CM prompted
investigation of a subset of non-natural amino acids that have
shown promise in peptide and protein modiﬁcation using oleﬁn
metathesis. Allyl-protected amino acids including serine,
cysteine, and selenocysteine have been shown to enhance the
rate of metathesis when incorporated into peptides and
proteins.38,75 Studies by Davis and co-workers ascribed the
unique chemical reactivity of such amino acids through a
chelation-assisted mechanism whereby precoordination of the
heteroatom to ruthenium increases the eﬀective concentrations
of the alkylidene and alkene without detrimental chelation.38
Moreover, softer nucleophiles such as sulfur and selenium were
found to have an activating eﬀect relative to oxygen for
enhancing the rate of CM. These ﬁndings are intriguing
considering that sulfur can have a deactivating eﬀect on oleﬁn
metathesis,76−78 and our results suggest that sulfur-containing
amino acids (e.g., compound 5l) lead to catalyst inactivity.
Nonetheless, a wealth of information suggests that heteroatoms
can modulate metathesis activity;79−81 however, this phenom-
enon was unexplored using Z-selective cyclometalated catalysts.
To investigate the inﬂuence of allylic heteroatoms on the
activities of catalysts 1 and 2, we examined a series of allyl-
protected amino acids in homodimerization (Table 6). We
chose allylglycine (9a) and homoallylglycine (9b), as well as
allyl-protected serine (9c) and cysteine (9d), for our studies. In
this sense, 9a−d would reveal both the role of sterics (i.e.,
comparison of 9a and 9b) and the eﬀect of chelation by
heteroatoms (i.e., comparison of 9b to 9c,d) in facilitating
metathesis. For these tests, we investigated homodimerization
of 9a and compared its reactivity relative to that of substrate 9b.
Conversion of 9a to the dimerized product 10a was low using
catalyst 1 or 2, occurring in 45% yield and 90% Z selectivity
(entry 1). By comparison, dimerization of homoallylglycine 9b
aﬀorded product 10b in 59% yield and 90% Z selectivity (entry
2). This corroborates our earlier ﬁndings that the steric
environment around the alkene can inﬂuence the eﬃciency of
Z-selective metathesis.58 We next evaluated the eﬀects of
heteroatoms in facilitating homodimerization. Allyl-protected
serine 9c aﬀorded product 10c in 67% yield with 92% Z
selectivity (entry 3). By comparison, cysteine 9d was more
active in homodimerization, leading to 71% yield and 93% Z
selectivity in the presence of catalyst 2 (entry 4). These results
suggest that allylic heteroatoms can facilitate Z-selective
metathesis in the presence of cyclometalated ruthenium
catalysts.
The insights garnered from the homodimerization of
substrates 9a−d revealed that the identity of the alkene can
inﬂuence the activities of catalysts 1 and 2 in Z-selective
metathesis. Although these studies provide important insight
for assessing the intrinsic reactivity of allyl-modiﬁed amino
acids with cyclometalated ruthenium catalysts, the general
utility of such catalysts could be further illuminated by their use
in CM. As such, we examined catalysts 1 and 2 in CM using
allyl-modiﬁed amino acids 9a−d (Table 7). To assess the
relative activities of substrates 9a−d in CM, we chose allyl
acetate 11 as the cross partner, as we previously showed that 11
is highly active in Z-selective CM.82 We explored a variety of
conditions to test the generality of CM including the use of
solvents that are compatible with native peptides and proteins.
For our initial studies, we examined CM between allylglycine
9a and 11 under our previously optimized conditions, and this
aﬀorded the heterocross product 12a in 42% yield and 90% Z
selectivity. We next explored CM under aqueous conditions,
including the use of additives shown to enhance the eﬃciency
of CM on peptides and proteins.83 In the presence of aqueous
tert-butanol, the heterocross product 12a was achieved in 38%
yield with 90% Z selectivity (entry 2). Inclusion of salts such as
LiCl or MgCl2, which has been shown to be beneﬁcial for
enhancing methathesis on peptides,84,85 aﬀorded product 12a
in 31% yield but with diminished Z selectivity (entries 3 and 4).
These trends were also observed using homoallylglycine 9b as
the cross partner (entries 5−8). To investigate whether amino
acids bearing allylic heteroatoms inﬂuence the eﬃciency of Z-
selective CM, we exposed allylserine 9c and allylcysteine 9d to
similar reaction conditions. Synthesis of the heterocross
product was improved, aﬀording 12c in 63% yield with 92%
Z selectivity using catalyst 2 (entry 9). The use of aqueous
conditions (entry 10) or inclusion of additives (entries 11 and
12) led to slightly diminished yields and Z selectivity. By
comparison, the use of allylcysteine 9d as the cross partner
aﬀorded the desired product 12d in 60% yield with 90% Z




entry equiv of 3 equiv of 5s 1 2 1 2
1 1 1 46 47 90 93
2 1 2 43 48 84 90
3 1 4 38 41 84 91
4 1 6 34 38 72 88
5 2 1 47 58 88 91
6 4 1 58 60 90 92
7 6 1 62 66 87 90
aIsolated yields. bDetermined by 1H or 13C NMR spectroscopy.





entry R product 1 2 1 2
1 CH2 (9a) 10a 44 46 88 93
2 CH2CH2 (9b) 10b 59 58 90 92
3 CH2OCH2 (9c) 10c 67 69 92 94
4 CH2SCH2 (9d) 10d 74 71 90 90
aIsolated yields. bDetermined by 1H or 13C NMR spectroscopy.
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selectivity (entry 13). As observed with substrates 9a−c, a
decrease in catalyst activity occurred under aqueous conditions
and in the presence of salt additives (entries 14−16).86
Collectively, these results suggest that the activities of catalysts
1 and 2 are highly dependent on the reaction conditions. In
general, the trends observed in CM with 9a−d parallel those
observed using nonchelated ruthenium catalysts;87 however, the
use of salts as additives appears to have a deactivating eﬀect on
the activity of cyclometalated ruthenium catalysts. These results
lend support to the importance of the chelating ligand (i.e.,
bidentate versus mondentate ligand coordination) in the
activities and selectivities of catalysts 1 and 2.
Z-Selective Cross Metathesis on Linear Peptides.
Investigation of both canonical and noncanonical amino acids
in homodimerization and cross metathesis revealed that the
choice of cross partner is critical to the success of ruthenium-
catalyzed Z-selective metathesis. In this regard, amino acid side
chains bearing aliphatic, aromatic, or protected polar
functionalities were highly active in metathesis. Those amino
acids that generally lead to lower conversion (i.e., arginine)
could undergo selective cross metathesis in the presence of a
more highly reactive substrate. Moreover, the steric environ-
ments around the oleﬁn and allylic heteroatoms were shown to
impact the eﬃciency of Z-selective CM. Whereas these
observations apply generally to amino acids that are commonly
used in oleﬁn metathesis, we wanted to investigate whether
cyclometalated ruthenium catalysts could be used in CM on
more complex substrates, including peptides. In choosing the
requisite cross partners, we took inspiration from peptides
known to adopt deﬁned β-sheet secondary structures when
tethered through a turn-promoting moiety or as part of a
macrocycle.88−90 Such structures hold promise in applications
ranging from supramolecular chemistry91,92 to biology93−95 and
oﬀer challenging substrates for catalysts 1 and 2.
A wealth of information regarding the use of peptides and
small molecules as β-sheet mimics has revealed that both
hydrogen bonding and amino acid side-chain pairing
preferences can be used to dictate the stability of β-sheet
formation.88,96,97 To this end, we synthesized peptides 13 and
14, which represent typical sequences found in parallel β-sheets
and whose structures are known to rely on the sequence of
amino acids (Scheme 1).88 For our studies, we used an excess
of peptide 13, as we had shown that less reactive amino acids,
including arginine, could be used for selective cross metathesis
in the presence of more highly active amino acids. Under these
conditions, conversion reached 60% for the desired peptide 15
with greater than 90% Z selectivity.98 Attempts to improve the
yield of the heterocross product by conducting CM in solvents
that promote hydrogen bonding and thereby preorganize the
peptides to facilitate metathesis99−101 led to similar con-
versions.102 These results attest to the functional-group
tolerability of cyclometalated ruthenium catalysts and point to
further strategies aimed at accessing complex oleﬁnic substrates
bearing multiple functionalities.
Z-Selective Ring-Closing Metathesis on α-Helical
Peptides. Our results regarding the activity of cyclometalated
ruthenium catalysts in cross metathesis of amino acids and
peptides revealed that the kinetic selectivities of catalysts 1 and
2 can be used to synthesize peptides highly enriched in Z-
oleﬁns. Although these studies provide a framework for
promoting metathesis through judicious choice of the amino
acid sequence, we observed that conversions in CM were
optimal at relatively high concentrations (∼0.3−0.4 M), which,
Table 7. Cross Metathesis of Allyl-Modiﬁed Amino Acids
with Allyl Acetate
yielda (%) Z selectivityb (%)
entry substrate product 1 2 1 2
1c 9a 12a 40 42 88 90
2
d 38 36 90 92
3e 31 31 76 84
4f 30 34 72 83
5c 9b 12b 56 55 90 95
6d 53 51 90 93
7e 48 50 84 87
8f 44 46 79 84
9c 9c 12c 63 66 88 92
10d 64 67 87 93
11e 54 61 67 79
12f 56 61 63 84
13c 9d 12d 62 61 88 90
14d 63 67 86 92
15e 55 60 74 88
16f 58 60 76 82
aIsolated yields. bDetermined by 1H or 13C NMR spectroscopy.
cReaction conditions: 1 mmol of 9a−d in THF. dReaction conditions:
1 mmol of 9a−d in 1:1 H2O/t-BuOH. eReaction conditions: 1 mmol
of 9a−d in 1:1 H2O/t-BuOH + 2 mM LiCl. fReaction conditions: 1
mmol of 9a−d in 1:1 H2O/t-BuOH + 2 mM MgCl2.
Scheme 1. Z-Selective Cross Metathesis on Peptides
aDetermined by analytical high-performance liquid chromatography mass spectrometry (HPLC-MS).
Journal of the American Chemical Society Article
dx.doi.org/10.1021/ja507166g | J. Am. Chem. Soc. 2014, 136, 12469−1247812473
for many substrates, might be a limitation. We sought a more
general strategy such that a variety of reaction conditions could
be used to promote Z-selective metathesis on a diverse
collection of peptides. To this end, we investigated ring-closing
metathesis (RCM) of oleﬁnic amino acids for the synthesis of
“stapled” peptides. Such peptides hold promise as novel
therapeutics by virtue of their enhanced α-helicity;41,103
proteolytic stability;34,42,104−108 and ability to target intra-
cellular proteins involved in cancer,32,39,47,104 infectious
disease,44−46 and metabolism.109 As such, we set about to
broaden the available catalysts used to synthesize this important
class of peptides under conditions that would be amenable to
comprehensive screening of catalyst activity in the presence of
varying peptide sequences.
Traditional methods for the synthesis of stapled peptides by
RCM have relied on the use of O-allyl serine28,29,110 or Cα-
tetrasubstituted amino acids41,111−113 to install macrocyclic
cross-links into synthetic peptides. Most strategies incorporate
non-natural amino acids at positions spanning one (i, i + 4) or
two (i, i + 7) turns of a helix that serve to preorganize the
reactive side chains on the same helical face. A wealth of
knowledge derived from computational114,115 and experimen-
tal47,116−118 approaches has illuminated the minimal constraints
necessary for achieving RCM on peptides using ﬁrst- and
second-generation or Grubbs−Hoveyda ruthenium cata-
lysts.119,120 An unmet challenge in the synthesis of stapled
peptides has been the ability to control oleﬁn geometry in the
product, as the use of noncyclometalated ruthenium catalysts
typically gives rise to both E and Z isomers that are often
inseparable. This imposes challenges for examining the role of
oleﬁn geometry in the stability and biological activity of stapled
peptides, which, to date, has not been thoroughly ex-
plored.106,121−123 To this end, we employed catalysts 1 and 2
in Z-selective RCM for stapling α-helical peptides that
encompass the vast majority of peptides used for biological
studies.
As part of our ongoing eﬀort to expand the utility of catalysts
1 and 2, we chose to conduct RCM on resin-supported
peptides. This would streamline the synthesis of peptides and
oﬀer a modular platform to test the activities of cyclometalated
ruthenium catalysts. Our goal was to compare the activities of
Z-selective catalysts with those of noncyclometalated ruthe-
nium catalysts in RCM, and we focused our eﬀorts on peptides
with known biological activity. The sequence we chose is
derived124 from an α-helical peptide known to target the BCL-2
family of proteins involved in the regulation of apoptosis and
whose activity is modulated by constraining the peptide
through hydrocarbon stapling (Table 8).34 The chemical
features of peptide 16 consist of two stereochemically deﬁned
α,α-disubstituted oleﬁnic amino acids125 separated by one turn
of a helix (i.e., oleﬁns positioned at residues i and i + 4) that,
upon ring closure, would generate a 21-membered macrocycle.
The stabilities and activities of catalysts 1 and 2 in the
presence of resins were unexplored, and we examined
commonly used resins for solid-phase peptide synthesis that
varied based on composition and loading capacity. Throughout
Table 8. Z-Selective RCM to form i, i + 4 Stapled Peptides
conversionb,c (%) Z selectivityd (%)
entry catalyst (mol %) resina time (h) 1 2 1 2
1 10 Wang 2 25 20 n.d. n.d.
2 10 TentaGel 2 40 30 n.d. n.d.
3 10 MBHA 2 60 55 n.d. n.d.
4 10 MBHA 4 70 60 >85 >90
5 10 (×2) MBHA 4 75 75 >85 >90
6 10 (×2) MBHA 4 80e 70 >85 >90
aLoading capacities for resin: Wang, 0.5 mmol/g; TentaGel, 0.25 mmol/g; MBHA, 0.5 mmol/g. bConversions determined by analytical HPLC of
cleaved peptide. cAmino acids were protected prior to RCM. dDetermined by analytical HPLC-MS. eReaction carried out at 40 °C.
Scheme 2. Z-Selective RCM to form i, i + 7 Stapled Peptides
aDetermined by analytical HPLC-MS.
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our studies, we performed RCM in solvents that promote α-
helicity [e.g., dicholorethane (DCE)] at concentrations that
favor macrocyclic ring closure. Initial screening revealed that
the choice of resin inﬂuenced the activities of catalysts 1 and 2
in RCM. Conversions to the desired RCM product 17 were
typically low on Wang resin using 10 mol % catalyst at room
temperature for 2 h (entry 1). Resins bearing hydrophilic
linkers proved beneﬁcial, aﬀording conversions approaching
40% under the same reaction conditions (entry 2). The use of
MBHA resin led to 60% conversion (entry 3), and we focused
further optimization using this resin. We next explored the
eﬀects of reaction time and catalyst loading on RCM.
Prolonging the reaction led to modest improvements,
generating product 17 in 70% conversion with greater than
90% Z selectivity (entry 4), and subjecting the resin-bound
peptide to successive rounds of catalyst111 resulted in
conversions of 75% using two cycles of catalyst addition
(entry 5). Increasing the temperature to 40 °C aﬀorded 17 in
80% yield and with greater than 90% Z selectivity (entry 6).126
To probe the generality of the method, we investigated
peptides bearing oleﬁnic amino acids spanning two turns (i, i +
7) of a helix with varying amino acid sequences (Scheme 2).127
To span the distance of two helical turns, we modiﬁed the N-
terminal oleﬁnic amino acid by increasing the tether length
(from ﬁve to eight carbon atoms) and inverting the
stereochemical conﬁguration (from S to R), both of which
were predicted to facilitate RCM.41,104,128 Under our optimized
conditions, conversions of 85% for the desired RCM product
19 could be achieved after two cycles of catalyst addition with
greater than 90% Z selectivity. These results demonstrate that
cyclometalated ruthenium catalysts can promote Z-selective
RCM on solid support for the synthesis of stapled peptides
bearing all hydrocarbon cross-links.
i, i + 3 Z-Selective Ring-Closing Metathesis Attempts
on Aib-Containing Peptides. We earlier demonstrated that
Aib-rich peptides bearing i, i + 3 L-serine O-allyl residues aﬀord
highly E-selective RCM products,110 in studies motivated, in
part, by a theoretical prediction that suggested an RCM-derived
18-membered ring using these side chains would serve as a
minimal constraint for the 310-helix.
129 We were curious to see
whether a Z-selective catalyst could overcome any substrate
bias favoring the E-oleﬁn geometry. To this end, we studied the
RCM conversions of pentapeptide Boc-L-Ser(Al)-Aib-Aib-L-
Ser(Al)-Aib-OMe (20) and heptapeptide Boc-L-Val-L-Ser(Al)-
L-Leu-Aib-L-Ser(Al)-L-Val-L-Leu-OMe (24) to macrocycles 21
and 25, respectively, using second-generation catalysts 22 and
23 and Z-selective catalyst 1 (Table 9). As expected from our
earlier studies, peptide 20 readily cyclized to the E macrocycle
in the presence of 10 mol % 22 or 23 in DCE held at 45 °C for
10 h (entries 1 and 2). Under similar reaction conditions, no
macrocyclization was observed with catalyst 1, even with a 3-
fold increase in catalyst loading and extended reaction time
(entry 3). The same behavior was observed for heptapeptide
24, although, in this case, the Z macrocycle did form with 22 or
23 to the extent of ca. 8% (entries 4 and 5). Peptide 24 rapidly
cyclized with the second-generation catalysts in reﬂuxing
dichloromethane, but it was unreactive toward catalyst 1
under identical conditions (entry 6). Whereas most peptide
side-chain RCM reactions produce E/Z mixtures, the minimal i,
i + 3 cross-link in these Aib-containing systems seems reluctant
to form the Z-oleﬁn, probably a consequence of the
conformational restrictions imposed by the Cα-tetrasubstituted
α-amino residues.130
These results demonstrate that the i + 1 and i + 2 Aib
residues play a role in controlling the E-selective RCM behavior
with catalysts 22 and 23 and this conformational bias cannot be
overcome by Z-selective catalysts. These studies highlight the
importance of peptide sequence and conformation in
controlling oleﬁn geometry in the macrocyclic product and
point to further strategies aimed at understanding how these
parameters aﬀect the eﬃciency of Z-selective RCM.
Table 9. RCM to Form i, i + 3 Stapled Peptides
entry substrate product catalyst (mol %) temperature (°C) time (h) conversiona (%) selectivity
1 20 21 22 (10) 45 10 86 >20:1 E/Zb
2 23 (10) 45 10 85 >20:1 E/Zb
3 1 (30) 40 21 <5 n.d.
4 24 25 22 (10) 45 3.5 100 13:1 E/Za
5 23 (10) 45 3.5 94 11:1 E/Za
6 1 (10) 40 4 <5 n.d.
aDetermined by analytical HPLC-MS. bDetermined by 1H NMR spectroscopy.
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■ CONCLUSIONS
In summary, we have reported the ﬁrst examples of Z-selective
metathesis on peptides using cyclometalated ruthenium
catalysts. By examining a broad range of canonical and
noncanonical amino acids in cross metathesis, homodimeriza-
tion, and ring-closing metathesis, we have gleaned important
criteria for achieving high conversion while maintaining
excellent Z selectivity. The following insights based on our
results are summarized:
The side-chain identity of an amino acid can dictate the
activities of catalysts 1 and 2 in cross metathesis and
homodimerization. In general, amino acids bearing aliphatic
or aromatic side chains (e.g., alanine, leucine, and phenyl-
alanine) are highly active in metathesis, with yields approaching
85% and 94% Z selectivity. Exceptions include glycine and
proline, as these are inactive in metathesis. Sterically hindered
side chains (e.g., valine or isoleucine) and amino acids bearing
bulky protecting groups lead to lower conversions but without
degradation of Z selectivity. Amino acids bearing carboxylate
functionalities (i.e., glutamic acid and aspartic acid) require
protection, as substrates bearing acidic functionalities can lead
to catalyst decomposition and diminished Z selectivity. Amino
acids bearing thiols or thioethers generally deactivate cyclo-
metalated ruthenium catalysts; however, in some cases, the use
of protecting groups can lead to productive turnovers. Side
chains bearing hydroxyl groups (e.g., serine or threonine) are
generally tolerated by catalysts 1 and 2, whereas amino acids
bearing heterocycles have variable activity. Tryptophan is active
in Z-selective homodimerization and cross metathesis, whereas
histidine is generally inactive. Polar side chains bearing
carboxamide (i.e., glutamine or asparagine) or guanidinium
(i.e., arginine) functionalities are generally intolerant of
cyclometalated ruthenium catalysts. Protection of these side
chains can restore catalyst activity, leading to products highly
enriched in Z-oleﬁns.
Cross metathesis and homodimerzation of amino acids and
peptides using Z-selective ruthenium catalysts can be
performed in a variety of solvents, provided that the acidity
of the reaction medium is kept minimal. The use of solvents
such as MeCN, DMSO, and DMF generally leads to lower
conversions than the use of noncoordinating solvents (e.g.,
DCE). The use of protic solvents (e.g., MeOH, EtOH, or H2O)
can lead to products enriched in Z-oleﬁns. Prolonged reaction
times in protic solvents can, in some cases, lead to
decomposition of catalysts 1 and 2.
Amino acids bearing allylic or homoallylic functionality are
active in Z-selective metathesis. In general, higher conversions
in homodimerization and CM can be achieved using
homoallylic functionalities, particularly for sterically hindered
substrates. Noncanonical amino acids containing allylic
heteroatoms including those that could be incorporated into
peptides and proteins are active in Z-selective cross metathesis
and follow trends similar to those of noncyclometalated
ruthenium catalysts. The use of aqueous conditions in the
presence of salts as additives appears to diminish the activities
of catalysts 1 and 2.
Cyclometalated ruthenium catalysts can be used to
synthesize stapled peptides bearing hydrocarbon oleﬁnic
cross-links positioned at residues i, i + 4 or i, i + 7. To probe
the limits of these catalysts in peptide stapling, we exposed Z-
selective catalysts to Aib-rich peptides bearing O-allyl serine
cross-links positioned at residues i and i + 3 that predominantly
give rise to highly E-selective macrocyclic products. In these
cases, catalysts such as 1 failed to undergo Z-selective RCM,
suggesting that conformational restrictions imposed by
substrates such as 20 can inﬂuence the activities of cyclo-
metalated ruthenium catalysts 1 and 2 in RCM.
Notably, compounds 15, 17, and 19 represent the most
complex substrates synthesized by cyclometalated ruthenium
catalysts, and this bodes well for further studies aimed at
applying Z-selective metathesis on substrates bearing multiple
functionalities. It is envisioned that the studies reported herein
will serve as a guideline in choosing appropriate alkene cross
partners or promoting RCM on peptides. We anticipate that
cyclometalated ruthenium catalysts could access new structures
and provide insight into the role of alkene geometry in the
biological activities of stapled peptides. Moreover, installation
of Z-alkenes into peptides and proteins could allow sites for
further modiﬁcations. Progress in the design and development
of stereoselective ruthenium catalysts will continue to broaden
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